MedPath

Apixaban

Generic Name
Apixaban
Brand Names
Eliquis, Apixaban Accord
Drug Type
Small Molecule
Chemical Formula
C25H25N5O4
CAS Number
503612-47-3
Unique Ingredient Identifier
3Z9Y7UWC1J
Background

Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.

Indication

Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.

Associated Conditions
Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of Apixaban in Korean Frail Atrial Fibrillation Patient

Active, not recruiting
Conditions
Atrial Fibrillation
First Posted Date
2023-03-17
Last Posted Date
2024-05-29
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
2500
Registration Number
NCT05773222
Locations
🇰🇷

Seoul National university Hostpital, Seoul, Jongno-gu, Korea, Republic of

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Phase 3
Recruiting
Conditions
Atrial Fibrillation
Interventions
Drug: Apixaban
Drug: Milvexian
Drug: Placebo
Drug: Apixaban Placebo
First Posted Date
2023-03-07
Last Posted Date
2025-01-10
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
20000
Registration Number
NCT05757869
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇺🇸

Holy Name Medical Center, Teaneck, New Jersey, United States

🇦🇷

CIDIM-Centro Integral de Diagnostico por Imagenes Marchegiani, Cordoba, Argentina

and more 1022 locations

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

First Posted Date
2023-02-21
Last Posted Date
2024-02-13
Lead Sponsor
Imperial College London
Target Recruit Count
6660
Registration Number
NCT05735639
Locations
🇬🇧

Imperial College Hospital NHS Foundation Trust, London, United Kingdom

DIrect Oral Anticoagulation and mechaNical Aortic Valve

Phase 4
Not yet recruiting
Conditions
Aortic Valve Disease
Interventions
Drug: Apixaban 5 MG Oral Tablet
First Posted Date
2023-01-18
Last Posted Date
2023-01-26
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
1044
Registration Number
NCT05687448
Locations
🇫🇷

Service de Cardiologie Hôpital Lariboisière, Paris, France

Venous Thromboembolism Prevention in Outpatients With Glioma

Phase 2
Not yet recruiting
Conditions
Astrocytoma
Glioblastoma
Venous Thromboembolism
First Posted Date
2023-01-13
Last Posted Date
2023-01-13
Lead Sponsor
University of Vermont Medical Center
Target Recruit Count
40
Registration Number
NCT05683808

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Phase 3
Terminated
Conditions
Prevention of Stroke or Systemic Embolism
Atrial Fibrillation
Interventions
Drug: Asundexian (BAY2433334)
Drug: Apixaban
Drug: Apixaban matching placebo
Drug: Asundexian matching placebo
First Posted Date
2022-12-08
Last Posted Date
2024-12-09
Lead Sponsor
Bayer
Target Recruit Count
14830
Registration Number
NCT05643573
Locations
🇨🇳

Hwa Mei Hospital, University of Chinese Academy Sciences, Ningbo, Zhejiang, China

🇨🇳

Xuanwu Hospital Capital Medical University, Beijing, China

🇨🇳

Beijing Tongren Hospital, Capital Medical University (West), Beijing, China

and more 1066 locations

Pharmacokinetics of Apixaban in Peritoneal Dialysis

Recruiting
Conditions
Atrial Fibrillation
Interventions
Drug: Apixaban
First Posted Date
2022-09-08
Last Posted Date
2024-06-25
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
50
Registration Number
NCT05532878
Locations
🇭🇰

Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong

Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury

Not Applicable
Recruiting
Conditions
Spinal Cord Injuries
Spinal Diseases
Interventions
Drug: Apixaban
Drug: Enoxaparin Sodium
First Posted Date
2022-08-02
Last Posted Date
2023-09-29
Lead Sponsor
Loewenstein Hospital
Target Recruit Count
60
Registration Number
NCT05484557
Locations
🇮🇱

Loewenstein Rehabilitation Hospital, Ra'anana, Israel

An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

Completed
Conditions
Prevention of Thromboembolic Events
Atrial Fibrillation
Interventions
Drug: Apixaban
First Posted Date
2022-07-25
Last Posted Date
2023-12-12
Lead Sponsor
Bayer
Target Recruit Count
600
Registration Number
NCT05471830
Locations
🇺🇸

Bayer, Whippany, New Jersey, United States

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)

Completed
Conditions
Venous Thromboembolism
Cancer
Treatment of Venous Thromboembolism in Cancer Patients
Interventions
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Apixaban
First Posted Date
2022-07-18
Last Posted Date
2022-10-26
Lead Sponsor
Bayer
Target Recruit Count
2437
Registration Number
NCT05461807
Locations
🇩🇪

Bayer, Wuppertal, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy